Official ERS guidelines, statements and technical standards

Official ERS guidelines, statements and technical standards on a wide range of respiratory topics, alongside ERS endorsed documents.

Apply to develop a guideline, statement or technical standard

ERS provides financial support to groups of members looking to form a Task Force to produce guidelines, statements and technical standards.

Guidelines, statements and technical standards in development

There are a number of ongoing ERS Task Forces and joint Task Forces creating guidelines, statements and technical standards for a wide range of respiratory topics.

Official ERS guidelines, statements and technical standards

Official ERS guidelines, statements and technical standards on a wide range of respiratory topics, alongside ERS endorsed documents.

Présenter une demande d'élaboration d'une ligne directrice, d'un énoncé ou d'une norme technique

Guidelines, statements and technical standards in development

All guidelines

Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline

Jussi J. Saukkonen, Raquel Duarte, Sonal S. Munsiff, Carla A. Winston, Manoj J. Mammen, Ibrahim Abubakar, Carlos Acuña-Villaorduña, Pennan M. Barry, Mayara L. Basto , Wendy Carr, Hassan Chami, Lisa L. Chen, Terence Chorba, Charles L. Daley, Anthony J. Garcia-Prats, Kelly Holland, Ioannis Konstantinidis, Marc Lipman, Giovanni Battista Migliori, Farah M. Parvez, Adrienne E. Shapiro, Giovanni Sotgiu, Jeffrey R. Starke, Angela M. Starks, Sanket Thakore, Shu-Hua Wang, Jonathan M. Wortham, Payam Nahid

Year:

2025

Type:

Clinical practice guidelines

Produced by:

ERS / ATS / IDSA / CDC

https://doi.org/10.1164/rccm.202410-2096ST

Background: On the basis of recent clinical trial data for the treatment of drug-susceptible and drug-resistant tuberculosis (TB), the American Thoracic Society, U.S. Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America have updated clinical practice guidelines for TB treatment in children and adults in settings in which mycobacterial cultures, molecular and phenotypic drug susceptibility tests, and radiographic studies, among other diagnostic tools, are available on a routine basis.

Methods: A Joint Panel representing multiple interdisciplinary perspectives convened with American Thoracic Society methodologists to review evidence and make recommendations using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) and GRADE-ADOLOPMENT (adoption, adaptation, and, as needed, de novo development of recommendations) methodology.

Results: New drug-susceptible TB recommendations include the use of a novel 4-month regimen for people with pulmonary TB and a shortened 4-month regimen for children with nonsevere TB. Drug-resistant TB recommendation updates include the use of novel regimens containing bedaquiline, pretomanid, and linezolid with or without moxifloxacin.

Conclusions: All-oral, shorter treatment regimens for TB are now recommended for use in eligible individuals.

CDN Connection Issue

Official ERS guidelines, statements and technical standards

Official ERS guidelines, statements and technical standards

Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline

Additional content

#{title}